Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex;Espectro clínico y valor diagnóstico de los anticuerpos contra el complejo proteico asociado a canales de potasio

Neurologia

Volumn 30, Issue 5, 2015, Pages 295-301

  Montojo, M T ^a,b   Petit Pedrol, M ^a,b   Graus, F ^a,b   Dalmau, J ^a,b,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Antibodies; Autoimmune; Encephalitis; Potassium channel

Indexed keywords

CELL SURFACE PROTEIN; CONTACTIN ASSOCIATED PROTEIN LIKE 2; LEUCINE RICH GLIOMA INACTIVATED PROTEIN 1; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL ANTIBODY; AUTOANTIBODY; CNTNAP2 PROTEIN, HUMAN; LGI1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN; PROTEIN; VOLTAGE GATED POTASSIUM CHANNEL;

BRAIN REGION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EXCITABILITY; MORVAN SYNDROME; MYELINATED NERVE; MYOKYMIA; NERVE CELL; NEUROLOGIC DISEASE; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NERVE HYPEREXCITABILITY; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SHORT SURVEY; FEMALE; HUMAN; IMMUNOLOGY; LIMBIC ENCEPHALITIS; MALE;

AUTOANTIBODIES; FEMALE; HUMANS; LIMBIC ENCEPHALITIS; MALE; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEINS;

EID: 84929654342     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2013.12.007     Document Type: Short Survey

References (31)

1. Newsom-Davis J., Buckley C., Clover L., Hart I., Maddison P., Tüzüm E., et al. Autoimmune disorders of neuronal potassium channels. Ann N Y and Sci 2003, 998:202-210.
2. Suleiman J., Brenner T., Gill D., Brilot F., Antony J., Vincent A., et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011, 76:1252-1255.
3. Lai M., Huijbers M.G., Lancaster E., Graus F., Bataller L., Balice-Gordon R., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: A case series. Lancet Neurol 2010, 9:776-785.
4. Lancaster E., Huijbers M.G., Bar V., Boronat A., Wong A., Martinez-Hernandez E., et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011, 69:303-311.
5. Klein C.J., Lennon V.A., Aston P.A., McKeon A., O'Toole O., Quek A., et al. Insights from LGI1 and Caspr2 Potassium cannel complex autoantibody subtyping. JAMA Neurol 2013, 70:229-234.
6. Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., et al. Antibodies to Kv1 potassium cannel-complex proteins leucine-rich glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
7. Vincent A., Irani S.R. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010, 5:S277-S280.
8. Rosenfeld M.R., Titulaer M.J., Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis. Five new things. Neurol Clin Pract 2012, 3:215-223.
9. Fukata Y., Lovero K.L., Iwanaga T., Watanabe A., Yokoi N., Tabuchi K., et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci USA 2010, 107:3799-3804.
10. Morante-Redolat J.M., Gorostidi-Pagola A., Piquer-Sirerol S., Sáenz A., Poza J.J., Galán J., et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet 2002, 11:1119-1128.
11. Kalachikov S., Evgrafov O., Ross B., Winawer M., Barker-Cummings C., Martinelli Boneschi F., et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002, 30:335-341.
12. Yu Y.E., Wen L., Silva J., Li Z., Head K., Sossey-Alaoui K., et al. Null mutation in mice exhibit myoclonic seizures and CA1 neuronal hyperexcitability. Hum Mol Genet 2010, 19:1702-1711.
13. Zhou L., Messing A., Chiu S.Y. Determinants of excitability at transition zones in Kv1.1-deficiente myelinated nerves. J Neurosci 1999, 19:5768-5781.
14. Bel C., Oguievetskaia K., Pitaval C., Goutebroze L., Faivre-Sarrailh C. Axonal targeting of Caspr2 in hippocampal neurons via selective somatodendritic endocytosis. J Cell Sci 2009, 122:3403-3413.
15. Alarcón M., Abrahams B.S., Stone J.L., Duvall J.A., Perederiy J.V., Bomar J.M., et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 2008, 82:150-159.
16. Friedman J.I., Vrijenhoek T., Markx S., Janssen I.M., van der Vliet W.A., Faas B.H., et al. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry 2008, 13:261-266.
17. Strauss K.A., Puffenberger E.G., Huentelman M.J., Gottlieb S., Dobrin S.E., Parod J.M., et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006, 354:1370-1377.
18. Iranzo A., Graus F., Clover L., Morera J., Bruna J., Vilar C., et al. Rapid eye movement sleep behaviour disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 2006, 59:178-181.
19. Andrade D.M., Tai P., Dalmau J., Wennberg R. Tonic seizures: A diagnostic clue of anti-LGI1 encephalitis?. Neurology 2011, 76:1355-1357.
20. Irani S.R., Michell A.W., Lang B., Pettingill P., Waters P., Johnson M.R., et al. Faciobraquial dystonic seizures precede LGI1 antibody limbic encephalitis. Ann Neurol 2011, 69:892-900.
21. Irani S.R., Pettingill P., Kleopa K.A., Schiza N., Waters P., Mazia C., et al. Morvan syndrome: A clinical and serological observations in 29 cases. Ann Neurol 2012, 72:241-255.
22. Montagna P., Agrypnia Lugaresi E. Excitata: A generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol 2002, 113:552-560.
23. Hart I.K., Waters C., Vincent A., Newland C., Beeson D., Pongs O., et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997, 41:238-246.
24. Vernino S., Lennon V.A. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 2002, 26:702-707.
25. Rubio-Agusti I., Perez-Miralles F., Sevilla T., Muelas N., Chumillas M.J., Mayordomo F., et al. Peripheral nerve hyperexcitability: A clinical and immunological study of 38 patients. Neurology 2011, 76:172-176.
26. Illingworth M.A., Hanrahan D., Anderson C.E., O'Kane K., Anderson J., Casey M., et al. Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol 2011, 53:1053-1057.
27. Brenner T., Sills G.J., Hart Y., Howell S., Waters P., Brodie M.J., et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013, 54:1028-1235.
28. Fujita K., Yuasa T., Watanabe O., Takahashi Y., Hashiguchi S., Adachi K., et al. Voltage-gated potassium channel complex antibodies in Creutzfeldt-Jakob disease. J Neurol 2012, 259:2249-2250.
29. Lachance D.H., Lennon V.A., Pittock S.J., Tracy J.A., Krecke K.N., Amrami K.K., et al. An outbreak of neurological autoimmunity with polyrradiculopathy in workers exposed to aerosolid porcine neural tissue: A descriptive study. Lancet Neurol 2010, 9:55-66.
30. Paterson R.W., Zandi M.S., Amstrong R., Vincent A., Schott J.M. Clinical relevance of positive voltage-gated potassium cannel (VGKC)-complex antibodies: Experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 2013, 10.1136/jnnp-2013-305218.
31. Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12:157-165.